| Building the Store for Healthcare | General Medicine | Raising Health | 2026-10-22 | | AI is making healthcare advice abundant. But what happens when you actually need to act on it? General Medicine CEO TJ Parker argues that the new bottleneck is getting the lab, booking the specialist, filling the prescription, or understanding what any of it will cost. At BUILD 2026, a16z General Partner Vineeta Agarwala sits down with TJ to unpack General Medicine's vision for a healthcare “store”: one place where patients can understand their options, prices, and insurance coverage, then actually get care. They discuss why convenience can materially change patient behavior, how AI can connect medical records and benefits to the right next step, and what TJ learned building PillPack and Amazon Pharmacy about making a complicated healthcare system feel simple. Resources: Follow TJ Parker: https://x.com/tjparker Follow Vineeta Agarwala: https://x.com/vintweeta Learn more about General Medicine: https://generalmedicine.co/ Learn more about a16z Bio + Health: https://a16z.com/bio-health/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| Mark Zuckerberg & Priscilla Chan: How AI Will Help Cure Disease | The a16z Show | 2026-07-09 | | As part of our summer replay series, we're revisiting one of our favorite conversations from the past year. Mark Zuckerberg and Dr. Priscilla Chan join Ben Horowitz, Vineeta Agarwala, and Erik Torenberg to discuss the Chan Zuckerberg Initiative's ambitious effort to help cure, prevent, and manage disease by the end of the century. Rather than funding individual breakthroughs, CZI is focused on building the tools and infrastructure that can accelerate scientific discovery across entire fields. The conversation explores Biohub, Cell Atlas, virtual cell models, open biological datasets, and the growing role of AI in helping researchers better understand human biology. They discuss why biology still lacks a "periodic table of elements," how AI could help scientists test hypotheses before running expensive experiments, and why pairing frontier biology with frontier AI may unlock a new era of medical discovery. Resources: Follow Mark Zuckerberg on X: https://x.com/finkd Follow Dr. |
| Mark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease | The a16z Show | 2025-11-06 | | Priscilla Chan and Mark Zuckerberg join a16z’s Ben Horowitz, Erik Torenberg, and Vineeta Agarwala to share how the Chan Zuckerberg Initiative is building the computational tools that will accelerate the cure, prevention, and management of all disease by century's end. They explain why basic science needs $100 million-scale projects that traditional NIH grants can't fund, how their Cell Atlas became biology's missing periodic table with millions of cells catalogued in open-source format, and why their new virtual cell models will let scientists test high-risk hypotheses in silico before investing in expensive wet lab work. Plus: the organizational shift unifying the Biohub under AI leadership, what happens when biologists and engineers sit side-by-side, and why modern biology labs are expanding compute instead of square footage. Timestamps: 4:17 - Building tools to accelerate scientific discovery 5:47 - The credible path to funding basic science 7:21 - Biohub = Frontier Biology + Frontier AI 9:05 - Challenges building on a 10-15 year timeline 9:43 - How CZI chooses what to work on 11:15 - Making sense of science with LLMs 11:31 - Measuring success in the therapeutic realm 13:32 - “Most diseases should be thought of as rare diseases” 15:39 - Inspiration: building a periodic table for biology 19:27 - Why virtual cells? |
| Value-Based Oncology at Scale: Inside Thyme Care | Raising Health | 2025-09-29 | | Cancer care in the U.S. costs over $250 billion each year, and nearly 2 million Americans receive a new diagnosis annually, yet too often the journey begins with silence: no call, no plan, no guide. In this episode, a16z’s Vineeta Agarwala and Jay Rughani talk with Thyme Care leaders Robin Shah (cofounder and CEO), Bobby Green, MD (president and CMO), and Brad Diephuis, MD (president and COO) about rebuilding oncology around the patient. They cover where the system breaks, how navigation plus value-based contracts align incentives, how AI can extend clinicians, and what scale looks like today, more than 83,000 active patients. A concise blueprint for truly patient-centered cancer care. Timecodes: 0:00 Introduction 1:47 Personal Stories & Early Days of Time Care 5:27 Building the Team & Mission 7:07 The Patient Journey: Where the System Fails 9:58 Why Tech Hasn’t Solved Cancer Care (Yet) 15:45 Scaling Impact: Growth & Partnerships 17:45 How Time Care Works: Value-Based Care Explained 23:15 Technology, AI, and the Human Touch 37:06 Building for the Future: Generational Impact Resources: Find Robin on LinkedIn: https://www.linkedin.com/in/robin-shah-8072bb35 Find Bobby on LinkedIn: https://www.linkedin.com/in/drbobbygreen/ FInd Brad on LinkedIn: https://www.linkedin.com/in/bdiephuis/ Find Vineeta on X: https://x.com/vintweeta Find Jay on X: https://x.com/JayRughani Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! |
| America's Autism Crisis and How AI Can Fix Science with NIH Director Jay Bhattacharya | The a16z Show | 2025-09-23 | | Dr. Jay Bhattacharya is one of the country’s top medical experts and a 24-year professor of medicine at Stanford. After being censored and deplatformed during COVID for his role in opposing harsh lockdowns, he was appointed Director of the National Institutes of Health by President Trump in 2025. a16z General Partners Erik Torenberg, Vineeta Agarwala, and Jorge Conde join Dr. Bhattacharya to discuss the administration’s role in tackling the autism crisis, how to restore public trust in health authorities, how to make the NIH more dynamic and efficient, and how to streamline publishing and restore academic freedom. Timecodes: 0:00 Introduction 1:30 Autism Initiative & New Research 2:45 Drug Discoveries: Leucovorin & Tylenol Caution 4:35 Preterm Birth & Broader Health Initiatives 5:45 The Replication Crisis in Science 8:50 Reforming NIH Funding & Scientific Culture 14:00 Allocation vs. Execution at NIH 17:30 Political & Scientific Decision-Making 22:30 Addressing Life Expectancy & Chronic Disease 27:00 Supporting Early Career Investigators 34:50 Academic Freedom & Open Science 37:30 Rebuilding Public Trust in Public Health 41:00 Communicating Science Amid Uncertainty 47:50 NIH Priorities: Nutrition, Chronic Disease, AI 50:00 The Future of AI in Science & Medicine 53:30 Advice for Rising Scientists 55:00 The Role and Limits of AI in Science Resources: Find Dr. |
| Episode 23: a16z's Vineeta Agarwala | BioVenture VoiCes with Chris Garabedian | 2025-07-28 | | Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the Broad Institute, Flatiron Health, and GV (Google Ventures). She talks about a16z's investment philosophy of "providing more than just a check," and a recent $500M fund partnered with Lilly. |
| Google Doubles Down on Cloud AI, Hulk Hogan Passes Away at 71, Hill and Valley Forum Reactions | Casey Neistat, Chris Samra, Zak Kukoff, Vineeta Agarwala, Micky Malka, Alex Hawkinson | TBPN | 2025-07-24 | | (00:14) - Timeline (05:16) - Google Doubles Down on Cloud AI (38:10) - Hulk Hogan Passes Away at 71 (49:49) - Timeline (57:44) - Zak Kukoff is a venture capitalist with over a decade of experience in the technology and venture capital sectors, focusing on early-stage investments and entrepreneurship. He currently serves as the Chair of the Tech and Venture Practice at Lewis-Burke Associates LLC and is a Non-Resident Senior Fellow at the Foundation for American Innovation. ([lewis-burke.com]( [thefai.org]( In the conversation, Kukoff discusses the recent interview of Trevor Milton on Tucker Carlson's show, expressing that it was a poor choice of platform and suggesting that a more direct approach to questioning, such as confronting Milton about specific fraud allegations, would have been more effective. (01:14:37) - Timeline (01:29:04) - Vineeta Agarwala, a general partner at Andreessen Horowitz, discusses the transformative role of AI agents in healthcare, highlighting their potential to revolutionize drug development and patient care. She emphasizes the increasing adoption of AI-driven tools to address labor shortages and improve efficiency, noting that both startups and established companies are integrating these technologies to enhance operations. Agarwala also points out the growing interest in open-source models within the biotech sector, facilitating rapid innovation and collaboration among researchers and organizations. |
| Scaling Medicaid Innovation with Afia Asamoah, Rajaie Batniji, and Sanjay Basu | Raising Health | 2025-01-14 | | Rajaie Batniji, MD, PhD, Afia Asamoah, JD, and Sanjay Basu, MD, PhD, cofounders of Waymark, join Vineeta Agarwala, MD, PhD, a16z Bio + Health general partner, to discuss their transformative approach to Medicaid care delivery. This episode dives into their rising risk signal prediction framework, where cutting-edge machine learning predicts patient needs and enables community-based care teams to reduce preventable ER visits and improve health outcomes at scale. The team recently published their real-world results—including a 23% reduction in unnecessary acute care—in the New England Journal of Medicine Catalyst. Additional resources: Supporting Rising-Risk Medicaid Patients Through Early Intervention , NEJM Catalyst The Body Economic : Why Austerity Kills, by David Stuckler and Sanjay Basu Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| Harnessing Water Dynamics for Drug Design with Michael Crackower and Jason Burch | Raising Health | 2024-08-20 | | Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health. Together, they talk about how Ventus approaches drug discovery and why they believe we’re in the early stages of small molecule innovation. Specifically, we’ll hear about the ReSOLVE platform, which enables the drug hunting team to more accurately design and iterate on small molecular compounds for therapeutic applications. They also talk about the current candidates in the pipeline and how they’re able to go from idea to IND in record time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| A Fatal Inheritance with Lawrence Ingrassia | Raising Health | 2024-07-16 | | Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health. Together, they discuss Larry's recently published book, A Fatal Inheritance: How A Family Misfortune Revealed A Deadly Medical Mystery . In the book, Larry recounts the story of the p53 cancer suppressor gene, also known as the “guardian of the genome.” Mutations in this gene, which can be inherited, remove a natural tumor defense, making it more likely for an individual to get cancer during their lifetime. He tells the story of the search for this gene and the scientists who unlocked the mystery of high familial incidences of cancer, Drs. Li and Fraumeni. He also shares a more personal aspect of the story: many members of his family inherited Li-Fraumeni Syndrome and suffered from multiple cancers themselves. |
| The Science and Supply of GLP-1s | The a16z Show | 2024-06-19 | | Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health. Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time. This is the second episode in Raising Health’s series on the science and supply of GLP-1s. Listen to last week's episode to hear from Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective. Listen to more from Raising Health’s series on GLP-1s: The science of satiety: https://raisinghealth.simplecast.com/episodes/the-science-and-supply-of-glp-1s-with-carolyn-jasik Payers, providers and pricing: https://raisinghealth.simplecast.com/episodes/the-science-and-supply-of-glp-1s-with-chronis-manolis Stay Updated: Let us know what you think: https://ratethispodcast.com/a16z Find a16z on Twitter: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Subscribe on your favorite podcast app: https://a16z.simplecast.com/ Follow our host: https://twitter.com/stephsmithio Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. |
| The Science and Supply of GLP-1s with Brooke Boyarsky Pratt | Raising Health | 2024-06-04 | | Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health. Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time. This is the second episode in our series on the science and supply of GLP-1s. Listen to last week's episode to hear from Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective. |
| Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery | The Long Run with Luke Timmerman | 2024-05-01 | | Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery. |
| Dark Genome Hunting with Rosana Kapeller and Marty Taylor | Raising Health | 2024-03-12 | | Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health. Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease. Additional reading: Structures, functions and adaptations of the human LINE-1 protein Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| Gate Unveiling with Jordi Mata-Fink | Raising Health | 2023-12-05 | | Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health. In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed 'molecular gates.' His company, Gate, is working to exploit a previously uncharted avenue in cell biology—the secretory translocon—for therapeutic intervention. This approach has the potential to combat diseases otherwise resistant to existing therapeutics. Jordi also imparts valuable insights on the power of platform-based problem-solving and team building. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| From Faculty to Founder: Building Startups from Academia | Raising Health | 2023-06-20 | | In this episode, taken from a live a16z event, Bio + Health general partner Vineeta Agarwala moderates a panel of UCSF faculty founders, including Michelle Arkin, Jimmie Ye, and Natalia Jura (full bios below). Together, they discuss fundraising, the decision to stay in or leave academia after founding a company, and their tips for managing the IP process. Michelle Arkin is a professor of pharmaceutical chemistry at UCSF, chair of the Department of Pharmaceutical Chemistry, and a co-director of the Small Molecule Discovery Center at UCSF. Professor Arkin is also a cofounder of both Elgin Therapeutics and Ambagon Therapeutics. Jimmie Ye is an associate professor of medicine at the Institute for Human Genetics at UCSF and an affiliate investigator at Gladstone Institutes. He is also the cofounder of Dropprint Genomics and Survey Genomics. Natalia Jura is a professor in the Department of Cell and Molecular Pharmacology and an investigator at the Cardiovascular Research Institute at UCSF. Professor Jura is also an associate director of the Quantitative Biosciences Institute. She is a cofounder of Rezo Therapeutics. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| Reengineering Healthcare and Medicine with Technology with Vineeta Agarwala | Raising Health | 2023-05-04 | | This is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health. Together, they chat about Vineeta's dual role as a clinician and investor, the adoption curve of digital therapeutics, how Vineeta thinks about platforms and a modular, engineering-driven approach to biotech, and much more. |
| Journal Club: Remodeling Oncogenic Transcriptomes with Ben Cravatt and Gene Yeo | Raising Health | 2023-04-06 | | Today marks the reboot of our journal club series, so you can look forward to seeing these episodes as part of our regular feed. This episode is a scientific deep dive on recent research published by Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute and co-founder of a diverse suite of chemoproteomic companies such as Vividion and Belharra Therapeutics, and Gene Yeo, Professor of Cellular and Molecular Medicine at the University of California, San Diego and co-founder of Locana Bio, Eclipse Bio, and Trotana Therapeutics. Ben and Gene are joined by Vineeta Agarwala, general partner at a16z Bio + Health, and bio deal team member Bryan Faust. Together, they’ll discuss some unexpected mechanistic results of finding covalent binders to a class of proteins that we are just starting to understand — RNA binding proteins — and the subsequent translational implications that they described in a recent paper published by the Cravatt and Yeo labs in Nature Chemical Biology. The paper outlines a potentially new therapeutic approach that uses small molecules to fundamentally rewire transcriptional networks in cancer cells. Additional reading: Remodeling oncogenic transcriptomes by small molecules targeting NONO |
| Live at HLTH: The Future of Venture Capital in Healthcare—featuring Dr. Vineeta Agarwala | The Beat | 2023-01-05 | | |
| CD: What Digital Health Needs to Get Right to Comprehensively Improve Care with Vineeta Agarwala, Physician, Investor, and General Partner at Andreesen Horowitz | Outcomes Rocket | 2023-01-05 | | Data can teach us about human health, it’s time to invest in it. In this episode, Vineeta Agarwala, physician, investor, and general partner at Andreesen Horowitz, commonly known as a16z, talks about digital health adoption and investing in companies with products that can pragmatically change patient care and increase workforce efficiency. Vineeta speaks about not only being an investor but also a practicing physician and how that impacts her perspective on innovative digital health startups and trends in the healthcare space. Tune in to this episode to learn about the direction the healthcare industry is heading in terms of digital health adoption! Click this link to the show notes, transcript, and resources: outcomesrocket.health |
| 18. Betting on Biology via Venture Capital w/ Vineeta Agarwala | EBRC In Translation | 2022-12-15 | | In this episode, we interview Vineeta Agarwala , MD, PhD, a general partner at Andreesen Horowitz (a16z) where she leads investments in the group’s bio + health fund . We talk to Vineeta about investing in synthetic biology startup companies, a day in the life of a VC, following the good people, and more! Disclosures: The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. |
| AI is Here. Now What? | Raising Health | 2022-12-01 | | AI is here...so why isn't it in every clinic? Eric Topol talks with a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb about what's taking so long, where AI can help patients and providers the most, what needs to happen to speed up adoption, and whether data or policy is more likely to be an obstacle. Eric has written extensively about AI in healthcare, including in his most recent book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again . He also writes a Substack focused on Covid research, called Ground Truths, linked below. Finally, as a marker of how AI and AI adoption has (and hasn't) changed over the last few years, check out Eric's 2019 interview with Vijay on the a16z Podcast, also linked below. Ground Truths - https://erictopol.substack.com/ a16z Podcast: AI and Your Doctor, Today and Tomorrow - https://a16z.com/2019/06/13/ai-doctor-deep-medicine-topol/ |
| Vineeta Agarwala - Venture Capital, a16z, and the MaML space | The MaML Podcast - Medicine & Machine Learning | 2022-06-23 | | Dr. Vineeta Agarwala is a general partner at a16z, physician, adjunct clinical professor at Stanford, previously at Google Ventures, Flatiron Health, having received her MD/PhD at Harvard Medical School and the Broad Institute. Many thanks to Ashlea Kosikowski from 1AB Media for making this episode happen! Follow us on twitter: @TheMaMLPodcast Host: David JH Wu @davidjhwu Producer: Aaron Schumacher @a_schu95 Design: Saurin Kantesaria |
| Uncontrolled Spread: Science, Policy, Institutions, Infrastructure | The a16z Show | 2021-09-20 | | There's no question technology played a huge role in the recent/current pandemic, including especially in the plug-and-play engineering and incredibly fast development behind the mRNA vaccines... But is there an even bigger role for the private sector, not just government, to play (and partner) when it comes to key infrastructure for future such emergencies, and even beyond? Especially given how faulty the translation of institutional science to policy and public health measures turned out to be -- for instance, with "6 feet" of social distancing, or with fomite (vs. aerosol) transmission of COVID. And why are we still talking about the same, not specific, vaccine booster for the Delta variant? What can we learn about real-world evidence, other clinical trial approaches, and progressive (vs. binary) EUA approvals when it comes to public health emergencies? Are capabilities like genomic surveillance and mapping strains -- which require layers of technology, real time -- sitting in the right places? In this special book-launch episode of the a16z Podcast, former FDA commissioner Dr. Scott Gottlieb -- author of the upcoming new book , Uncontrolled Spread: Why COVID-19 Crushed Us, and How We Can Defeat the Next Pandemic -- shares insights on the above, and revealing stories from behind the scenes. Do we need a new entity to manage public health through a national security lens, and is the government capable? |
| Leveraging Your Superpowers with Dr. Vineeta Agarwala (Andreessen Horowitz) | Spotlight on Women in Health Ventures | 2021-08-11 | | Vineeta Agarwala, MD, PhD, is a General Partner at Andreessen Horowitz (a16z) and adjunct clinical professor in the Division of Primary Care and Population Health at Stanford. She previously worked as a management consultant at McKinsey and as a Director of Product Management at Flatiron Health. At a16z, she works with companies seeking to improve how drug development and patient care delivery is done. We discuss with Dr. Agarwala the importance of adopting a “continuous learner” mindset, how to make the jump from academia to entrepreneurship, and trends in biotech and health tech, including a DoorDash-infrastructure for healthcare delivery. |
| Venture capital meets primary care (or PC2VC) | Healthy Conversations | 2021-06-11 | | Daniel is a physician who wears many hats: inventor, founder, investor, and startup advisor. This week he sat down with another physician, Dr. Vineeta Agarwala, who has taken her clinical expertise to a whole other industry. Vineeta is a General Partner at Andreessen Horowitz, where she leads investments for the storied firm’s bio fund (overseeing therapeutics, diagnostics, and digital health). |
| Precision Pioneers EP 7: Dr Vineeta Agarwala on investing in the future of precision medicine at the a16z bio fund | The Genetics Podcast | 2021-06-07 | | Can the speed and success of COVID-19 trials teach us how to run other trials 5x faster going forward? Can polygenic risk scores be effectively integrated into healthcare systems? Why do 'unique datasets' hold the key to future drug discovery? And why is there a disparity between precision medicine development in cancer and all other disease areas? Dr Vineeta Agarwala, General Partner at the Andreessen Horowitz Bio Fund, answers all these questions and more as she discusses the future of biotech and genomic medicine with Patrick. |
| a16z Bio + Health #13: Care After COVID with Shantanu Nundy | a16z Live | 2021-05-11 | | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, Vijay Pande, and Jorge Conde talk to guest Shantanu Nundy, the Chief Medical Officer of Accolade. The conversation covers Dr. Nundy's new book, " Care After Covid: What the Pandemic Revealed Is Broken in Healthcare and How to Reinvent It ", the next steps in the evolution of hospitals, interoperability (or lack thereof), and more. |
| a16z Bio + Health #11: The Digital Health OGs | a16z Live | 2021-04-28 | | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, and Jorge Conde talk to guests Sean Duffy, cofounder and CEO of Omada Health, Karan Singh, cofounder and COO of Ginger, and Chris Hogg, a serial entrepreneur in the digital health space. The conversation covers go-to-market strategies, financing and aligning incentives, the struggles of interoperability (or lack thereof), and what it is like to build today versus in the early years. |
| a16z Bio + Health #10: The Digital Health Difference with Connie Chen | a16z Live | 2021-04-21 | | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, and Jorge Conde talk to guest Connie Chen, Chief Medical Officer at Lyra health. The conversation covers what makes digital health different from traditional healthcare delivery, how to build a sustainable business model while maintaining high standards for care, and advice for founders of digital health startups. |
| a16z Bio + Health #9: Engineering CRISPR with Ben Oakes | a16z Live | 2021-04-08 | | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala and Vijay Pande talk to guest Ben Oakes, cofounder, President and CEO of Scribe Therapeutics. The conversation covers the the power of engineering gene editors, the transition from academia to a startup, and how to select the first indication to target with a novel bio platform. |
| a16z Bio + Health #8: How to Innovate within Biopharma with Jay Bradner | a16z Live | 2021-04-01 | | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guest Jay Bradner, President of the Novartis Institute of Biomedical Research (NIBR). The conversation covers the challenges of translating basic research into a clinical application, the state of innovation in therapeutics, and the transition from drug hunting to drug farming. |
| a16z Bio + Health #7: The Power of Patient Data with Anne Wojcicki | a16z Live | 2021-03-30 | 37 min | |
| The U.S. Vaccine Rollout | 16 Minutes News by a16z | 2021-03-20 | | Today on our news analysis show 16 Minutes — since this show is all about teasing apart what’s hype/ what’s real and where we are on the long arc of innovation — we're taking a quick pulse-check with the experts on just where we are with the COVID vaccine rollout in the U.S. Our experts today are Dr. Bob Wachter , the Chair of the Department of Medicine at UCSF — he has come to additional prominence during the pandemic as a regular public resource, providing daily updates & reports on Twitter throughout the crisis. He’s also currently guest-hosting the “In the Bubble” podcast. We also have Dr. Vineeta Agarwala , a general partner in a16z bio who is also a practicing clinician at Stanford Hospital. You can catch our ongoing coverage of all things vaccines at a16z.com/vaccines . But in this episode we cover where we really are right now with the vaccine rollout — is it working or not, given all the buzz and mixed messages we’ve been hearing on social and in the media? We cover everything from distribution, in practice (that is, from the clinical/ on-the-ground perspective); to other dynamics (such as new strains), to demand for the vaccines (including vaccine hesitancy, and it's not just about anti-vaxxers); to the data (which is where we start). On Friday the CDC reported that about 77 million people in the U.S. have currently received at least one dose of a COVID vaccine, with about 42 million who have been fully vaccinated. |
| a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside | a16z Live | 2021-03-18 | | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences. The conversation covers the growing role of artificial intelligence and machine learning in drug development and specifically in biologics and protein therapeutics. |
| a16z Bio + Health #5: From COVID to Consumerism & the Future of Virtual First Care with Stephen Klasko | a16z Live | 2021-03-13 | | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Julie Yoo, Vineeta Agarwala, Jorge Conde, and Vijay Pande, along with market development partner Venkat Mocherla, talk to guest Dr. Stephen Klasko, the president of Thomas Jefferson University and CEO of Jefferson Health about transforming the US healthcare system. |
| a16z Bio + Health #4: The History and Future of Genome Engineering with George Church | a16z Live | 2021-03-10 | | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande, along with a16z cofounder Marc Andreessen, talk to guest Dr. George Church of Harvard University about past, future, and power of genome engineering. |
| a16z Bio + Health #3: Metabolic Health with Casey Means | a16z Live | 2021-03-09 | | On this episode of the new a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Jeff Jordan, and Vijay Pande, talk to guest Dr. Casey Means, co-founder of Levels Health, about metabolism and metabolic health. |
| a16z Bio + Health #2: Digital Diagnostics with Gaurav Singal | a16z Live | 2021-02-26 | | On this episode of the new a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Vijay Pande, talk to guest Dr. Gaurav Singal about the future of digital diagnostics: what are they, who stands to benefit from them, and critically, who pays. |
| What to Know about Those Vaccines | The a16z Show | 2020-11-20 | | A vaccine for COVID seems to be (almost) here… or is it? What’s hype/ what’s real beyond the headlines (and beyond the press release), when it comes to the announcement last week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19 -- and relatedly, the most recent news around Moderna's vaccine candidate? Of course, this was just the first interim efficacy analysis — so how close or far are we? What’s the significance of the readout and case numbers? How do we put all this in context of all the other (458!) programs in development? And how much should/ shouldn’t we read into the news, given the buzzy excitement and penchant for evaluating "science via press release"? a16z bio general partners Vineeta Agarwala and Jorge Conde recently broke it all down in conversation with Sonal Chokshi on our show 16 Minutes: the math, the science, and the practical considerations — from “vaccine efficacy” vs. efficiency, from cold chains to distribution, from patients to the system… as well as why mRNA matters in the present future of vaccines. |
| Covid Vaccine! Beyond Science via Press Release | 16 Minutes News by a16z | 2020-11-14 | | A vaccine for COVID seems to be (almost) here... or is it? What's hype/ what's real beyond the headlines (and beyond the press release), when it comes to the announcement earlier this week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19? Of course, this was just the first interim efficacy analysis -- so how close or far are we? What's the significance of the readout and case numbers? How do we put this (and related approaches, like Moderna's) in context of all the other (458!) programs in development? And how much should/ shouldn't we read into this news? After all, it's "difficult to evaluate science via press release", as some say. So in this episode of 16 Minutes with a16z bio general partners Vineeta Agarwala and Jorge Conde in conversation with Sonal Chokshi, we break it all down: the math, the science, and the practical considerations -- from "vaccine efficacy" vs. efficiency, from cold chains to distribution, from patients to the system... as well as from the past, to present future of, vaccines. references and readings cited in this episode: BioCentury.com/coronavirus , COVID-19 therapies and vaccines: Clinical; COVID-19 therapies and vaccines: Preclinical; COVID-19 Clinical Trial Dashboard, November 2020 " Vaccine Efficacy 101: A biostatistician's primer ", Natalie E. Dean, Twitter, September 2020 " Understanding COVID-19 vaccine efficacy ", Marc Lipsitch and Natalie E. |
| A Faster, Cheaper Test -- Will It Really Democratize Coronavirus Testing? | 16 Minutes News by a16z | 2020-09-02 | | In this episode of 16 Minutes, we cover the recent news around the FDA's Emergency Use Authorization approval of Abbott Lab's latest COVID-19 test , which takes 15 minutes and will cost $5. At that speed and price point -- as well as the fact that it doesn't require lab equipment at point of care -- it should definitely increase testing capacity, making it a potential " game changer " in this pandemic... But does it truly democratize coronavirus testing (in an available-to-everyone-everywhere way)? How is and isn't it like a pregnancy test , and when or how would we be able to administer it everywhere and by anyone? To help tease apart what's hype/ what's real -- as is the premise of this show -- a16z bio general partner Vineeta Agarwala breaks it all down with host Sonal Chokshi in ~18 minutes. The conversation provides an overview of RT-PCR vs. antigen test types (and differences between "rapid" versions of both); digs into what the data does and doesn’t tell us here; and explains key concepts that everyone needs to know, including the " positive predictive value ", which has implications for widespread detection and testing. Agarwala (who is also a practicing physician) also briefly touches on practical considerations from the clinical perspective... what do we really need when the winter flu season hits? |
| Deep clinical annotation & hybrid startups with Vineeta Agarwala (Andreessen Horowitz + Stanford) | The Data Pulse | 2020-08-25 | | Today I speak with Vineeta Agarwala, General Partner at Andreessen Horowitz and a physician at Stanford. She shares the importance of capturing time-course, evolving data on patients that range from the molecular to the clinical levels ("deep clinical annotation"), as well as key ingredients of a successful tech-biotech hybrid startup. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary |
| Virtual Oncology | The a16z Show | 2020-04-10 | | with @vintweeta @pbcancerdoc @sumitshahmd @omnivorousread Coronavirus is now disrupting the entire health care system, not just because of the burden of dealing with the actual disease itself, but because of everything else that's had to grind to a halt. One of the areas where we really worry about things coming to a total stop like that is, of course, cancer treatment, which can often feel like a race against the clock even under the best conditions. In this episode, Dr. Bobby Green, MD (Community Oncologist and Chief Medical Officer, Flatiron Health) and Dr. Sumit Shah (Oncologist and Head of Digital Health, Stanford Cancer Center) join a16z's Vineeta Agarwala (physician and general partner) and Hanne Tidnam to talk about what is happening to oncology during the outbreak—how treatment is affected; what kind of clinical decisions oncologists and patients are having to make, and how they're making them; the tech tools that specialists are using, and how they could improve; and what happens to oncology as a whole when it's forced to go virtual. |
| Scaling Medicaid Innovation with Rajaie Batniji, Sanjay Basu, and Afia Asamoah | The a16z Show | | | |
| The Bioverge Podcast: Reengineering Healthcare and Medicine with Technology | Bioverge | | | |